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Introduction {#path5384-sec-0001}
============

Uveal melanoma (UM) is the most common primary intraocular cancer in adults, accounting for 5% of all melanomas [1](#path5384-bib-0001){ref-type="ref"}. Treatment options for primary UM (pUM) include radiotherapy and surgery [2](#path5384-bib-0002){ref-type="ref"}, and usually achieve excellent local tumour control. Despite this, about 50% of UM patients develop metastatic disease, mainly in the liver [1](#path5384-bib-0001){ref-type="ref"}. The average survival of patients with metastatic UM (mUM) is ∼12 months, as there are currently no proven effective treatments [3](#path5384-bib-0003){ref-type="ref"}. Resection of isolated liver metastases may be attempted in selected cases, otherwise liver‐directed therapy (e.g. percutaneous perfusion with melphalan) or systemic chemotherapy. Recently, following the striking benefits in metastatic skin melanoma, immunotherapy using immune checkpoint inhibitors (ICIs) has been more widely used in cancer. However, in marked contrast to cutaneous melanoma, mUM is almost universally refractory to ICIs, mostly against CTLA‐4 and PD1/PDL‐1, with responses to single agents in the range of 3--8% [3](#path5384-bib-0003){ref-type="ref"}.

While UMs have been partly ascribed to a low mutational burden [4](#path5384-bib-0004){ref-type="ref"}, [5](#path5384-bib-0005){ref-type="ref"}, evidence of specific TCR gene expression in tumour‐infiltrating lymphocytes (TILs) [6](#path5384-bib-0006){ref-type="ref"}, promising responses to adoptive cell therapy using TILs [7](#path5384-bib-0007){ref-type="ref"}, and encouraging results on targeting the melanocyte‐specific gp100 with the bispecific molecule tebentafusp (IMCgp100) [8](#path5384-bib-0008){ref-type="ref"} all suggest a specific immune response and that mutational burden is not the sole reason for the lack of response to ICI.

Monosomy 3 (M3) has long been known to be associated with increased risk of UM metastasis [9](#path5384-bib-0009){ref-type="ref"}, [10](#path5384-bib-0010){ref-type="ref"}, [11](#path5384-bib-0011){ref-type="ref"}, and more recently, it has become apparent that this is primarily due to inactivating mutations of the *BAP1* gene, which has been reported to be a stronger prognosticator than M3 [12](#path5384-bib-0012){ref-type="ref"}, [13](#path5384-bib-0013){ref-type="ref"}. The Cancer Genome Atlas (TCGA) study of 80 pUMs demonstrated that patients with pUM at high metastatic risk \[i.e. with UM characterised by M3 and loss of function of the tumour suppressor gene *BAP1* (Chr 3p21.1)\] could be further stratified, according to the presence of CD8^+^ T‐cell immune infiltrates and an altered transcriptional immune profile [4](#path5384-bib-0004){ref-type="ref"}. The latter included elevated levels of HLA‐I molecules, which leads to natural killer (NK) cell suppression [14](#path5384-bib-0014){ref-type="ref"}, TAM markers and expression of immune checkpoint regulators (ICRs), such as PD‐L1, indoleamine 2,3‐dioxygenase (IDO)‐1, and T‐cell Ig and ITIM domain (TIGIT) [4](#path5384-bib-0004){ref-type="ref"}, [15](#path5384-bib-0015){ref-type="ref"}.

Interestingly, previous work showed that loss of *BAP1* in turn affects the expression of genes that impact the immune response [16](#path5384-bib-0016){ref-type="ref"}. In this study, a comprehensive immune profiling of the 80 pUMs from the TCGA‐UM study revealed that several immune‐suppressive genes are significantly upregulated following *BAP1* loss. We provide a novel and comprehensive understanding of UM immune evasion by profiling primary and metastatic UM at the transcriptomic and protein level using cutting‐edge approaches, including mass cytometry, NanoString, and digital spatial profiling of human patient tissues. Our findings suggest that UM cells, particularly those of BAP1‐negative (BAP1^−^) UM, shape the immune profile at both primary and metastatic sites, harnessing the expression of particular pathways and molecules to drive regulatory functions of myeloid cells and lymphocytes, and thus immunosuppression and immunotherapy resistance in advanced UM. These findings provide new insight for the functional validation of detected biomarkers for the further development of novel adjuvant immunotherapeutic approaches.

Materials and methods {#path5384-sec-0002}
=====================

Human subjects {#path5384-sec-0003}
--------------

This work was underpinned by the University of Liverpool (UoL) Ocular Oncology Biobank (OOB) and the Liverpool Bioinnovation Hub Biobank. Project specific approvals for work with pUM and mUM samples were obtained (REC‐18/LO/1027). Four fresh enucleated pUMs were included in this study for the CyTOF analyses.

TCGA analysis {#path5384-sec-0004}
-------------

mRNA expression and clinical data of The Cancer Genome Atlas (TCGA) GDC Ocular Melanomas dataset (UVM) were downloaded from the Xena Functional Genomics Explorer of University of California, Santa Cruz (<https://xenabrowser.net/heatmap>) [17](#path5384-bib-0017){ref-type="ref"}. To provide understanding of the biological pathways involved in pUM pathogenesis via the expression of different immune genes, the nCounter PanCancer Immune Profiling gene set of 730 genes (NanoString Technologies, Seattle, WA, USA) was applied in the UCSC Cancer Genomics Browser to analyse the enrichment of immune genes sorted by *BAP1* mRNA expression or chromosome 3 copy number variations. Generated data were extracted in comma‐separated values (CVS) format and analysed in GraphPad Prism 6 (GraphPad Software, Inc, San Diego, CA, USA) for correlation studies. Supervised clustering of immune genes of the TCGA RNA‐seq dataset was performed among those with significant Spearman\'s correlation to *BAP1* expression or chromosome 3 copy number variation and sorted from the lowest rank (negative correlation) to the highest rank (positive correlation). The list of sorted genes was then uploaded in the Xena Browser for generation of heatmaps. Each of these genes was individually analysed as a prognosticator marker in Kaplan--Meier curves at the Xena Browser along the TCGA‐UM cohort. Those genes predicting significant survival differences (*p* \< 0.05) were selected for further immune network analysis using the nCounter immune category list (NanoString Technologies) complemented by a custom‐built leukocyte functional immune response network collated by literature review (supplementary material, Table [S1](#path5384-supitem-0005){ref-type="supplementary-material"}). Network plots were generated using the NodeXL Basic add‐in to Excel. In brief, immune genes were assigned to different immune categories in separated columns. In our analysis, we also considered the low‐ and high‐variance state of these genes along the TCGA‐UM cohort. This, in part, helped to define our hypothesis that the degree of variation in the expression of the genes associated with a particular network is indicative of the plasticity of that network [18](#path5384-bib-0018){ref-type="ref"}. Therefore, high variance is associated with increased plasticity (higher thickness of network lines) and low variance with diminished plasticity (lower thickness of network lines) in response to *BAP1* expression changes. We calculated the expression variance (σ^2^) of genes across the TCGA‐pUM cohort to predict how *BAP1* loss impacts upon the expression of a particular gene by applying the following formula: σ^2^ = ∑(*X −* μ*)* ^2^/*N*, where *X* represents the RNA‐seq expression value of a particular gene, μ is the mean of the entire RNA expression for this particular gene in the cohort, and *N* is the distribution number (TCGA‐UM, *N* = 80). Therefore, the higher the effect of *BAP1* on the gene expression, the higher the σ^2^ value of this particular gene in the cohort. In the network analysis, the highest variance value was limited to 5 units, assuming the *CCL24* gene as reference for the highest variance (σ^2^ = 35.7). Sphere size represents the number of genes assigned to a given immune category (supplementary material, Tables [S2](#path5384-supitem-0006){ref-type="supplementary-material"} and [S3](#path5384-supitem-0007){ref-type="supplementary-material"}). Box and whiskers analysis of specific genes according with different *BAP1* expression levels was performed. RNA levels of *BAP1* were defined as high (*n* = 27), mid (*n* = 26), or low (*n* = 27) according to a Kaplan--nMeier survival analysis of three groups in the TCGA‐UM cohort generated in the Xena Browser for *BAP1* gene expression (*p* = 0.004843 and log‐rank test statistic = 10.66).

Immunohistochemistry {#path5384-sec-0005}
--------------------

FFPE pUM and mUM samples were sectioned at 4 μm thickness and underwent antigen retrieval using the Dako pretreatment module (Agilent Technologies UK Ltd, Stockport, UK); slides were then incubated in a high‐pH bath containing Tris/EDTA buffer, pH 9.0 (Dako EnVision™ FLEX, Agilent) at 96°C for 20 min. IHC was performed using a Dako Autostainer PLUS machine, using the Dako Envision™ FLEX Kit (Agilent) according to the manufacturer\'s instructions. Slides were incubated with the following antibodies for 30 min: BAP1 (cat. No sc‐28 383/C‐4, dilution 1:200; Santa Cruz Biotechnology, Dallas, TX, USA), CD3 (cat. No IR503/polyclonal, ready to use; Dako Cytomation, CA, USA), CD4 (cat. No NCL‐L‐CD4/368, dilution 1:20; Leica Biosystems, Lincolnshire, IL, USA), CD8 (cat. No M7103/ C8/144B, dilution 1:200; Dako), CD163 (NCL‐L‐CD163/10D6, dilution 1:400; Leica Biosystems), and CD38 (NCL‐L‐CD38‐290/SPC32, dilution 1:100; Leica Biosystems).

The sections were counterstained with haematoxylin. Additional sections were treated with isotype controls at the same concentration as the primary antibodies.

Mass cytometry antibodies and reagents {#path5384-sec-0006}
--------------------------------------

All metal‐chelated optimised antibodies and reagents were purchased from Fluidigm (San Francisco, CA, USA). Full information for the antibodies and reagents used are provided in supplementary material, Table [S4](#path5384-supitem-0008){ref-type="supplementary-material"}. The Maxpar Human Immune Monitoring Panel Kit was used as a reference antibody panel to immune profile primary uveal melanoma tumours, which includes the immune markers recommended by the Human ImmunoPhenotyping Consortium (HIPC) [19](#path5384-bib-0019){ref-type="ref"}, with some modifications. The antibodies used cover the phenotype and functions of different subpanels of B cells, T cells, monocytes, dendritic cells, and NK cells. The MaxPar Panel Designer browser (Fluidigm) was used to predict and avoid metal spillover among tagged metals of the following additional markers included in the customised panel: CD74, LAG‐3, CD56, CD16, CTLA‐4, CD11b, and CD62L. The following markers were removed from the panel design in order to avoid spillover: CD194, TCRγδ, CD185, CD45RO, CD24, CD197, and CD20. Final spillover results were considered low between channels and this is shown in supplementary material, Figure [S1](#path5384-supitem-0002){ref-type="supplementary-material"}A, top. The final wheel‐heatmap of the customised antibody panel shows the function that determines the best antibody--tag combinations to minimise background among channels, which ultimately contains targets with low tolerance of signal overlap (yellow‐green).

Mass cytometry of pUM {#path5384-sec-0007}
---------------------

Four fresh histopathologically‐phenotyped BAP1^−^ pUMs were manually minced prior to enzymatic digestion using collagenase A (cat. No C9722, 2 mg/ml; Sigma Aldrich, St Louis, MO, USA) and 40 units/ml DNase‐I (cat. No 79254; Qiagen, Germantown, MD, USA) in DMEM and incubated with agitation at 37°C for 60 min in a thermal mixer (Thermo Fisher, Waltham, MA, USA). Following incubation, digests were passed through a 70 μm filter to remove residual particulates. Cells were then pelleted (centrifugation at 1500 rpm for 5 min), washed in PBS, and viable cells were quantified using a Trypan Blue exclusion viability dye. Live cells were then washed twice with ice‐cold cell staining buffer (ic‐CSB; Fluidigm) and total cell concentration was determined using a Neubauer chamber. Up to three staining reactions of a maximum of 2.0 × 10^6^ cells per sample were analysed. All samples were then incubated with 50 μl of 2% mouse serum in PBS with human TruStain FcX solution (Biolegend, San Diego, CA, USA) at 4 °C for 15 min. Samples were then processed for surface and intracellular staining with the panel described in supplementary material, Table [S4](#path5384-supitem-0008){ref-type="supplementary-material"} using the following protocol: 50 μl of a 2X surface antibody solution was made in ic‐CSB (final antibody dilution 1:100) and left on ice for 30 min. Cells were washed and fixed in 5 m[m]{.smallcaps} BS3 (Sigma) for 30 min, followed by fixation using 1x Fix‐I buffer according to the manufacturer\'s protocol (Fluidigm), and permeabilised in ice‐cold methanol for 10 min. Cells were washed and incubated with internal antibody cocktail (final dilution 1:100) for 30 min in ice. Then cells were washed and resuspended in intercalator‐Ir at 1:8000, and processed to be analysed using a Helios mass cytometer (Fluidigm).

Analysis of human tumour mass cytometry datasets {#path5384-sec-0008}
------------------------------------------------

Data from mass cytometry were normalised to the EQ 4‐element bead signal using normalisation software version 2 (Fluidigm). Live Ir^+^CD45^+^ cells were manually gated as previously described [20](#path5384-bib-0020){ref-type="ref"} (supplementary material, Figure [S1](#path5384-supitem-0002){ref-type="supplementary-material"}A, bottom), and FCS files were downloaded for concatenated analysis using Cytosplore V.2.2.1 for further downstream analysis by hierarchical stochastic neighbour embedding (HSNE) using a coefficient of 4 [21](#path5384-bib-0021){ref-type="ref"}, or individually processed for visualisation of t‐distributed stochastic neighbour embedding (viSNE) analysis in Cytobank. For accurate clustering and frequency calculations, a cut‐off of 1000 events was considered for the final gate. Eventually, Ir^hi^ CD45^+^ tumour infiltrated cells are detected among singlets and exhibit specific TAM markers, but not lymphocytic markers, excluding the possibility of doublets. These cells may often carry tumour‐derived DNA and melanin content given to phagocytosed tumour cells and are often observed in primary uveal melanoma tumours, classified as melanophages [22](#path5384-bib-0022){ref-type="ref"}.

Mass cytometry and NanoString data (transcriptomic and DSP data) have been deposited at Flow CyTOF data, <https://flowrepository.org/id/FR-FCM-Z2FD> and GEO (gene datasets, GSE145782).

mRNA expression analysis using NanoString technology {#path5384-sec-0009}
----------------------------------------------------

For RNA immune gene expression analysis, four pUMs, six mUMs, and one normal liver (NL) formalin‐fixed, paraffin‐embedded (FFPE) samples were used. Only the tumour areas were selected for RNA extraction, or the entire normal liver tissue. The RNeasy FFPE Kit (Qiagen) was used for tissue dissociation, RNA extraction, and purification according to the manufacturer\'s instructions (Qiagen), as described in supplementary material, Supplementary materials and methods.

The NanoString nSolver 2.6 software was used for normalisation of expression counts using housekeeping genes following the manufacturer\'s recommendations [23](#path5384-bib-0023){ref-type="ref"}. Data are displayed in expression count units of individual gene per patient compared with normal liver tissue, and internally normalised within each immune category (e.g. CTL suppression, M2 macrophage regulation, and immune checkpoint regulators). A full range of immune categories is displayed in supplementary material, Table [S1](#path5384-supitem-0005){ref-type="supplementary-material"}.

Digital spatial profiling of mUM tissues {#path5384-sec-0010}
----------------------------------------

Digital spatial profiling analysis of one BAP1^−^ mUM case was performed by NanoString\'s DSP technology platform to enable digital characterisation of protein distributed on the surface of FFPE tissue sections using the Human Immune Oncology panel (NanoString Technologies). In brief, 4‐ to 6‐μm‐thick FFPE mUM sections were stained for lymphocytes (CD3, red), macrophages (CD68, magenta), S100B (green), and DNA (blue) in order to detect the regions of interest (ROIs). The following workflow was used: deparaffinisation of FFPE unstained sections, antigen retrieval, antibody staining, ROI selection, DSP technology processing, nCounter analysis system. Data analysis and quality control were processed and normalised using positive and negative anti‐mouse and anti‐rabbit hybridisation control antibodies. S6 ribosomal protein and histone 3 were used as reference proteins. Area normalisation was applied between different ROI sizes varying from 100 to 650 μm in diameter. Results are displayed as absolute expression counts normalised with negative IgG controls.

Quantification and statistical analysis {#path5384-sec-0011}
---------------------------------------

All data were analysed using GraphPad Prism 6.0 and are presented as the means ± SD. Significant differences in the immune gene expression between the *BAP1* ^lo^, *BAP1* ^mid^, and *BAP1* ^hi^ groups were estimated using one‐way analysis of variance followed by Bonferroni\'s multiple comparisons test. Survival analysis was performed in the Xena Browser using the Kaplan--Meier assay and was compared using the log‐rank test. The correlation between different mRNA expressions and overall survivals (OS) of TCGA‐UM patients was evaluated by non‐parametric Spearman\'s correlation, two‐tailed, where \*0.01 \< *p* \< 0.05, \*\*0.001 \< *p* \< 0.01; \*\*\*0.0001 \< *p* \< 0.001, and \*\*\*\**p* \< 0.0001 were considered to indicate significant differences.

Results {#path5384-sec-0012}
=======

*BAP1* loss significantly correlates with the modulation of immune genes and patient survival in UM {#path5384-sec-0013}
---------------------------------------------------------------------------------------------------

In the previous TCGA‐UM analysis, Robertson *et al* reported that the M3 phenotype in UM is associated with the upregulation of 30 immune genes [4](#path5384-bib-0004){ref-type="ref"}, [24](#path5384-bib-0024){ref-type="ref"}, and we therefore first sought to investigate whether this association could be the result of *BAP1* loss. We found that an absence or reduced expression of *BAP1* mRNA (cut‐off 19.54 for *BAP1* expression and 2500 days as the default end‐point) also significantly correlated with decreased survival, similar to M3 status (cut‐off −0.3649 for Chr3 copy number and 2500 days as the default end‐point) (Figure [1](#path5384-fig-0001){ref-type="fig"}A). Using Spearman\'s correlation analysis, we demonstrate that most of the investigated immune genes have a better expression correlation with *BAP1* mRNA loss than with M3 (Figure [1](#path5384-fig-0001){ref-type="fig"}B). In addition, only about 50% of these genes are significantly associated with patient survival, indicated by blue squares representative of Kaplan--Meier statistical test results (Figure [1](#path5384-fig-0001){ref-type="fig"}B and supplementary material, Table [S5](#path5384-supitem-0009){ref-type="supplementary-material"}).

![*BAP1* loss significantly correlates with the modulation of immune genes and patient survival in pUM. (A) Decreased mRNA expression of *BAP1* is significantly correlated with a poor survival of primary UM patients similarly to the monosomy 3 (M3) status in the TCGA cohort. (B) Spearman\'s correlation analysis of specific immune genes compared to *BAP1* expression and to chromosome 3 (Chr3) copy number variation. (C) Venn diagram depicting immune genes with significant correlation to Chr3 and *BAP1* and with predictive survival significance. (D) Heatmap cluster analysis sorted by *BAP1* expression showing upregulated and downregulated immune genes, including the *P* value profile of Kaplan--Meier survival scores.](PATH-250-420-g001){#path5384-fig-0001}

We further expanded this analysis by interrogating the TCGA‐UM RNA‐seq data with a panel of 730 immune genes defined by the nCounter PanCancer immune panel (NanoString Technologies). One hundred and forty‐two immune genes exclusively correlated with *BAP1* expression, but not with chromosome 3 copy number variation (supplementary material, Table [S6](#path5384-supitem-0010){ref-type="supplementary-material"}); the expression of 117 genes negatively and another 25 genes positively correlated with *BAP1* expression (*r* scores varying from −0.53 to 0.46). Among 181 immune genes that significantly correlated with both *BAP1* expression and chromosome 3 copy number variation, 151 genes were negatively correlated and 30 genes were positively correlated, all with a higher correlation score to *BAP1* expression than to chromosome 3 (*r* scores varying from −0.60 to 0.67) (supplementary material, Table [S7](#path5384-supitem-0011){ref-type="supplementary-material"}). Among *BAP1* correlated genes (*n* = 323), 168 genes that were negatively correlated with *BAP1* expression were significantly associated with decreased survival, while 15 genes positively correlated with *BAP1* expression were significantly associated with improved survival (Figure [1](#path5384-fig-0001){ref-type="fig"}C and supplementary material, Table [S8](#path5384-supitem-0012){ref-type="supplementary-material"}).

Independent of *BAP1* expression, the M3‐UM genotype exclusively correlates with 43 immune genes and with 82 immune genes that also correlate with *BAP1* to a lower degree (supplementary material, Tables [S9](#path5384-supitem-0013){ref-type="supplementary-material"} and [S10](#path5384-supitem-0014){ref-type="supplementary-material"}), from which 48 are upregulated immune genes and 17 are downregulated immune genes, all significantly associated with patient survival (Figure [1](#path5384-fig-0001){ref-type="fig"}C and supplementary material, Table [S11](#path5384-supitem-0015){ref-type="supplementary-material"}). Supervised clustering analysis based on *BAP1* mRNA expression is shown, including the *P* value profile of each gene related to survival outcome (Figure [1](#path5384-fig-0001){ref-type="fig"}D). These findings suggest that loss of *BAP1* expression is strongly associated with immune modulation of the microenvironment in pUM.

*BAP1* loss correlates with immunosuppressive networks in pUM {#path5384-sec-0014}
-------------------------------------------------------------

We next analysed the group of immune genes upregulated following *BAP1* loss, to predict the likely effects on the microenvironment. A scatter plot shows the gene expression and variance of 168 upregulated immune genes following *BAP1* loss along the TCGA‐UM cohort, highlighting important immune genes involved in immune‐suppressive pathways, including *LGALS3*, *CD74*, *CD38*, *PDCD1*, *IDO1*, and *HLA‐DR* (Figure [2](#path5384-fig-0002){ref-type="fig"}A). Differential expression analysis revealed that most of these immune genes are significantly upregulated in the TCGA‐UM cohort following *BAP1* loss, as shown in the second quadrant of the volcano plot (Figure [2](#path5384-fig-0002){ref-type="fig"}B and supplementary material, Table [S8](#path5384-supitem-0012){ref-type="supplementary-material"}). *PDCD1* and *IDO1* have high significance with −log *P* values higher than 1.5 and log~2~FC lower than 0.2, and for that reason are not visible in the volcano plot.

![*BAP1* loss correlates with increased regulatory immune networks in primary uveal melanoma. (A) Gene expression profile of the TCGA‐UM cohort (*n* = 80) sorted from genes with the highest (left) to the lowest (right) gene variance expression. (B) Volcano plot depicting the most significantly upregulated immune genes with *BAP1* loss (black arrows), which have potential immunosuppressive functions. (C) Immune network subcategory integrations with upregulated genes following *BAP1* loss. The left panel shows general immune response networks and the right panel shows an expanded leukocyte effector immune response network. (D) Box and whiskers plots of selected upregulated and downregulated immune genes according to *BAP1* expression levels (high, mid, and low). One‐way ANOVA was used for statistical analysis with Bonferroni\'s multiple comparisons test. \*\*\*\**p* \< 0.00001, \*\*\**p* \< 0.0001, \*\**p* \< 0.001, \**p* \< 0.05.](PATH-250-420-g002){#path5384-fig-0002}

Importantly, all *BAP1* significantly correlated immune genes simultaneously integrate different subcategories of the immune response, which were used to build an interactive transcriptomic network for visualisation of the predominant immune profile driven by pUM with *BAP1* loss. Therefore, we performed a gene network analysis using two classification systems: a general immune response network based on major immune categories, and an amplified leukocyte functional immune network. In this analysis, the variance of gene expression (σ^2^) is represented by the thickness of the network lines, indicating the plasticity of the network toward *BAP1* loss.

This analysis demonstrated that most of modulated immune genes correlate with leukocyte functions, and some of them with chemokine, interleukin, and cytokine expression; B‐cell functions; TLR and TNF superfamilies; and antigen presentation processes (Figure [2](#path5384-fig-0002){ref-type="fig"}C). Within the leukocyte network, a dominance of immune‐suppressive pathways was observed, represented by red lines predominantly with higher expression variance (higher thickness), including Treg functions, Th1 suppression, Th2 activation, T‐cell tolerance responses, homing of Tregs, M2 macrophage functions, and ICRs (Figure [2](#path5384-fig-0002){ref-type="fig"}C). Immune networks related to effective anti‐tumour immune responses are represented by green lines, predominantly with lower expression variance (lower thickness).

Importantly, some of the few immune genes that are downregulated following *BAP1* loss (*MICA*, *TNFSF13*, and *CD44*) are important for the activation of anti‐tumour immune responses [25](#path5384-bib-0025){ref-type="ref"}, [26](#path5384-bib-0026){ref-type="ref"}, [27](#path5384-bib-0027){ref-type="ref"}, as shown in box and whisker plots together with other immunosuppressive and exhaustion‐related genes (i.e. *HLA‐DOB*, *CD74*, *CD38*, *LGALS3*, *IDO1*, *TIGIT*, *LAG3*, and *CD96*) (Figure [2](#path5384-fig-0002){ref-type="fig"}D). Although HLA‐DR has been classified as an immune response activation gene in disease given its importance in peptide presentation to CD4^+^ T cells [28](#path5384-bib-0028){ref-type="ref"}, many regulatory functions have been attributed to HLA‐DR expression in the context of cancer [29](#path5384-bib-0029){ref-type="ref"}. For that reason, in the network analysis, HLA‐DR was classified as immunosuppressive, although the generic immune activation classification was kept in Figure [2](#path5384-fig-0002){ref-type="fig"}D. Immune genes that have a significant correlation with M3 status but do not correlate with *BAP1* expression are probably regulated by different mechanisms that exclude *BAP1* involvement. Among these genes, those related with immune response activation are downregulated, including *IL12RB12*, *TLR1*, and *TLR5*, and those involved with suppression of immune response are upregulated, including *FN1*, *CD70*, and *CD73* (*NTFE*) (supplementary material, Figure [S2](#path5384-supitem-0003){ref-type="supplementary-material"}A,B). All together, these findings show how different immune genes may integrate similar immune‐suppressive categories in high‐risk *BAP1* ^−^ pUM, suggesting an importance in regulating the immune profile of mUM.

Transcriptomic analysis of mUM reveals a similar gene expression profile to *BAP1* ^*−*^ pUM {#path5384-sec-0015}
--------------------------------------------------------------------------------------------

In order to compare the transcriptomic immune profiles of the primary and metastatic sites of UM, we performed a NanoString assay interrogating the expression profile of the nCounter PanCancer Immune Profiling panel using four pUMs and six mUMs, all lacking nuclear BAP1 expression. Unsupervised cluster analysis was performed revealing a high correlation between most pUM and mUM cases, with the exception of one mUM (mUM‐06). No significant correlation was observed between a normal liver control and tumour tissues (Figure [3](#path5384-fig-0003){ref-type="fig"}A).

![Transcriptomic analysis of *BAP1*‐negative metastatic uveal melanoma reveals similar immune profiles to *BAP1*‐negative primary tumours. (A) Heatmap of unsupervised clustering of all the samples \[mUM (*n* = 6), pUM tissues (*n* = 4), and one normal liver\] and all the transcripts (nCounter 730 immune genes panel). (B) Spearman\'s correlation analysis of gene expression between unmatched tumours from four pUMs and five mUMs (left), two matched tumours from one UM patient using Spearman\'s correlation rank (*r* = 0.92, *p* \< 0.0001) (middle), and pUM/mUM NanoString data correlation analysis with TCGA‐UM Fpkm‐uq + 1 normalised RNA‐seq data (right). (C) Heatmap views of normalised RNA expression counts from six mUMs and one normal liver depicting the expression profile of CTL/NK suppression markers, immune checkpoint regulatory markers, and M2 macrophage regulation markers. Asterisks highlight selected highly expressed immune genes across the tissues.](PATH-250-420-g003){#path5384-fig-0003}

Spearman\'s correlation test of the total gene expression counts revealed significant similarity between the gene expression of both primary and metastatic groups (*r* = 0.92, *p* \< 0.0001) for *BAP1* correlated immune genes (supplementary material, Table [S8](#path5384-supitem-0012){ref-type="supplementary-material"}) (Figure [3](#path5384-fig-0003){ref-type="fig"}B, left). A similar correlation score was also observed for one patient with matched primary and metastatic samples (Figure [3](#path5384-fig-0003){ref-type="fig"}B, middle). Importantly, because the expression of samples of the same cancer generated using the same methodology and normalisation are often very similar, we also evaluated the correlation between our NanoString dataset (normalised counts) and the different samples of the TCGA‐UM cohort by applying the same genes. We observed that the normalised RNA‐seq data from the TCGA‐UM cohort are still highly correlative with the NanoString data, for both the primary and the metastatic tumours (Figure [3](#path5384-fig-0003){ref-type="fig"}B, right).

Strikingly, when comparing the gene expression of six mUM patients with that of one human disease‐free liver normal biopsy (normal liver, NL), most mUM patients displayed upregulation of specific immune genes related to suppression of cytolytic T cells (CTLs) (Figure [3](#path5384-fig-0003){ref-type="fig"}C), including HLA‐DRA, LGALS3, and CD38 partially [30](#path5384-bib-0030){ref-type="ref"}, [31](#path5384-bib-0031){ref-type="ref"}, [32](#path5384-bib-0032){ref-type="ref"}, [33](#path5384-bib-0033){ref-type="ref"}, [34](#path5384-bib-0034){ref-type="ref"}, [35](#path5384-bib-0035){ref-type="ref"}, [36](#path5384-bib-0036){ref-type="ref"}, [37](#path5384-bib-0037){ref-type="ref"}, [38](#path5384-bib-0038){ref-type="ref"}; ICRs such as *TIM‐3* (*HAVCR2*), *HMGB1*, *IDO1*, *LAG3*, and *CD73* (*NT5E*) [39](#path5384-bib-0039){ref-type="ref"}, [40](#path5384-bib-0040){ref-type="ref"}, [41](#path5384-bib-0041){ref-type="ref"}, [42](#path5384-bib-0042){ref-type="ref"}, [43](#path5384-bib-0043){ref-type="ref"}, [44](#path5384-bib-0044){ref-type="ref"}; and TAM functional markers, such as *ANXA1*, *CD74*, *CD9*, *INFAR2*, *MIF*, *PLA2G6*, and *CD163* [36](#path5384-bib-0036){ref-type="ref"}, [45](#path5384-bib-0045){ref-type="ref"}, [46](#path5384-bib-0046){ref-type="ref"}. In addition, transcript levels of *NOS2*, a predominant M1 macrophage marker [47](#path5384-bib-0047){ref-type="ref"}, were similar to the levels found in normal liver without tumours. We also found high expression levels of *CD74* and the macrophage migration inhibitory factor (*MIF*) across mUM tissues compared with normal liver. RNA levels of *CD38* were increased compared with the levels found in normal liver. At the protein level, we found that *CD38* was also positively expressed among regions of T‐cell infiltrates in one BAP1^*−*^ mUM case, as evidenced by IHC staining (supplementary material, Figure [S3](#path5384-supitem-0004){ref-type="supplementary-material"}H). B cells are nearly absent (low numbers of CD20^+^ cells) in mUM, and cytolytic effector cells seem to be at low activation states, given a paucity of TIA1^+^ cells among the TILs.

These findings suggest that the immune profile of *BAP1* ^*−*^ pUM is similar to mUM at the transcriptome level, suggesting an important role of CTL suppressive molecules, including HLA‐DRA and CD38, and TAM‐related pathways, where the CD74/MIF axis seems to play an important role driving the M2‐like phenotype and potential local tolerogenic responses. Therefore, some of these markers were further evaluated at the protein level of BAP1^−^ pUM.

High‐resolution single‐cell analysis reveals regulatory T‐cell phenotype and a mixed macrophage phenotype within pUM with nuclear BAP loss {#path5384-sec-0016}
------------------------------------------------------------------------------------------------------------------------------------------

In order to phenotypically and functionally characterise pUM at the protein level, we performed a high‐resolution single‐cell analysis using mass cytometry in five pUMs, four of which showed nuclear BAP1 loss and one with normal nuclear BAP1 expression. Among infiltrating CD45^+^ cells, we observed a predominant cluster of macrophages, T lymphocytes (CD8^+^ and CD4^+^ T cells), B cells, and DCs, as evidenced in HSNE plots of all samples clustered together (Figure [4](#path5384-fig-0004){ref-type="fig"}A,B). The frequency of each cell subtype was calculated for samples. The breakdown of the CD45^+^ infiltrating immune cells in BAP1^−^ samples was as follows: CD4^+^ T cells (12%), CD8^+^ T cells (37%), DCs (10%), macrophages (30%), and B cells (11%) (Figure [4](#path5384-fig-0004){ref-type="fig"}C, left). For one BAP1^+^ case, the breakdown of the CD45^+^ infiltrating immune cells was as follows: CD4^+^ T cells (14%), CD8^+^ T cells (59%), DCs (3%), macrophages (22%), and B cells (2%) (Figure [4](#path5384-fig-0004){ref-type="fig"}C, right).

![Mass cytometry analysis of infiltrated immune cells in primary UM. (A) Hierarchical stochastic neighbour embedding (HSNE) analysis showing the density of CD45^+^ infiltrated immune cells and selected phenotyping markers of concatenated pUM patients (BAP1^−^, *n* = 4 and BAP1^+^, *n* = 1). (B) Colour HSNE maps representing the phenotype of infiltrated immune cell subclusters. (C) Pie frequency charts of infiltrated immune cell subtypes detected by HSNE analysis for BAP1^−^ and BAP1^+^ tumours. (D) Heatmap displaying normalised marker expression of each immune cell cluster for four concatenated BAP1^−^ pUM samples. Analysis was generated in *Cytosplore* highlighting the most frequent clusters of CD45^+^ infiltrated immune cells, and an expanded analysis among tumour infiltrated monocytes, T lymphocytes, and B cells. (E) Pie chart showing the frequency of each cluster identified in HSNE analysis across the four merged BAP1^−^ pUM tumours.](PATH-250-420-g004){#path5384-fig-0004}

High‐dimensional HSNE single‐cell frequency clustering analysis and t‐SNE analysis (BAP1^−^ cases) were performed among CD45^+^ cells for pUM cases in order to detect major clusters among the different cell subtypes (Figure [4](#path5384-fig-0004){ref-type="fig"}D,E and supplementary material, Figure [S1](#path5384-supitem-0002){ref-type="supplementary-material"}B--D). Across the T‐lymphocyte compartment, we observed high expression levels of CD28 receptor on both CD4^+^ (cluster A) and CD8^+^ T cells (clusters B and C), with low expression of CTLA‐4 and LAG‐3 checkpoint inhibitors (Figure [4](#path5384-fig-0004){ref-type="fig"}D,E, and supplementary material, Figure [S1](#path5384-supitem-0002){ref-type="supplementary-material"}D). Two out of four patients have low CD28 expression in CD8^+^ T‐cell clusters (supplementary material, Figure [S1](#path5384-supitem-0002){ref-type="supplementary-material"}D), but no conclusions can be made, given the low number of tumours investigated. However, the frequency of CD28^+^CD8^+^ cells is still lower than CD28^+^CD4^+^ T cells in all four cases examined. CD4^+^ T cells mostly express CD25 and CD127 markers (cluster A, 5.1%), suggesting that they have a T‐regulatory phenotype [48](#path5384-bib-0048){ref-type="ref"}, [49](#path5384-bib-0049){ref-type="ref"}, [50](#path5384-bib-0050){ref-type="ref"}, [51](#path5384-bib-0051){ref-type="ref"}, [52](#path5384-bib-0052){ref-type="ref"}. In addition, CD8^+^ T cells were positive for the proliferation marker Ki67 (clusters B--D), which had low expression among CD4^+^ T cells (cluster A) (Figure [4](#path5384-fig-0004){ref-type="fig"}D). The high levels of Ki67 can be partially explained by the greater frequency of proliferating CD8^+^ T cells compared to CD4^+^ T cells. Cluster C (CD38^+^HLA‐DR^+^CD8^+^ T cells) is the most frequent CD8^+^ T‐cell cluster among BAP1^−^ tumours (13.5%) and also showed increased expression of CD74 (Figure [4](#path5384-fig-0004){ref-type="fig"}D,E).

In accordance with this suppressive phenotype, most CD8^+^CD28^+^ T cells (clusters B--D) were HLA‐DR^+^, a phenotype typical of regulatory CD8^+^ T cells [28](#path5384-bib-0028){ref-type="ref"}. Importantly, CD8^+^ T‐cell clusters express high levels of CD38, recently reported to drive regulatory functions on CD8^+^ T cells [38](#path5384-bib-0038){ref-type="ref"}, [53](#path5384-bib-0053){ref-type="ref"}. Although B cells are not predominant in pUM, they could be divided into three subclusters: CD25^+^CD11b^+^ (cluster H), CD25^low^CD11b^+^ (cluster I), and CD25^−^CD11b^−^CD74^+^ B cells (cluster J) (Figure [4](#path5384-fig-0004){ref-type="fig"}D,E). Interestingly, cluster H showed increased expression of the LAG‐3 immune checkpoint regulator. In the macrophage and dendritic cell compartment (MOs and DCs), we found a mixed phenotype of M2‐like CD68^+^CD163^+^CD74^+^ macrophages (cluster E, 7.7%), M1‐like CD68^+^CD163^−^CD74^−^CD11c^+^CD11b^+^ macrophages (cluster F, 9.7%), and myeloid CD68^−^CD11b^+^CD11c^+^ dendritic cells (cluster G, 7.8%).

No significant differences were observed in the subclusters analysed in the pUM BAP1^+^ sample for the different immune cell subtypes compared with the BAP1^−^ cases, apart from the CD8^+^ T‐cell compartment, which showed reduced levels of regulatory CD38^+^HLA‐DR^high^CD8^+^ T‐cell cluster (cluster N,19.9%) compared with BAP1^−^ tumours, and positive levels of the functional clusters CD38^−^HLA‐DR^low^Ki67^+^CD8^+^ T cells (cluster K 30.8%) and CD38^−^HLA‐DR^low^Ki67^−^CD8^+^ T cells (cluster M, 4.9%) and exhausted CTLA‐4^+^HLA‐DR^low^CD8^+^ T cells (cluster L, 3.4%) (supplementary material, Figure [S1](#path5384-supitem-0002){ref-type="supplementary-material"}B,C).

Taken together, we describe the regulatory nature of TILs in UM with nuclear BAP1 loss, particularly CD4^+^ and CD8^+^ T cells, and a mixed macrophage phenotype where M2‐like macrophages express higher levels of CD74.

Immune profile of mUM in regions of interaction between macrophages and lymphocytes {#path5384-sec-0017}
-----------------------------------------------------------------------------------

A digital spatial profiling assay (DSP, NanoString) revealed the protein expression profile of 31 immune markers in different regions of interest where macrophages (CD68) and lymphocytes (CD3) localised simultaneously in two mUM cases with nuclear BAP1 loss. Co‐localisation of macrophages and lymphocytes occurred both within and at the edge of the tumours (Figure [5](#path5384-fig-0005){ref-type="fig"}A). Among the cancer‐related markers, we observed the expression of β2M, STAT3, STING, and β‐catenin (Figure [5](#path5384-fig-0005){ref-type="fig"}B). The expression of β2M suggests that tumour antigens are presented via HLA‐A in these tumour areas, thus supporting the efficacy of ICI [54](#path5384-bib-0054){ref-type="ref"}. Total levels of STAT3 were elevated, but not in its activated phosphorylated form (pY705), which regulates gene transcription for modulation of immunosuppressive factors [55](#path5384-bib-0055){ref-type="ref"}. The expression of STING suggests a macrophage‐mediated hepatic inflammation and fibrogenic process [56](#path5384-bib-0056){ref-type="ref"}.

![Digital spatial profiling analysis of two mUM BAP1‐negative FFPE tissues using the NanoString immune oncology protein panel. (A) Regions of interest (ROI) to evaluate fibrotic areas with high infiltration of both macrophages (CD68) and lymphocytes (CD3). (B) Heatmap representation of different cancer‐related markers, immune phenotyping markers, and immune checkpoint and functional markers, all at the protein level among individual ROIs using normalised raw NanoString counts.](PATH-250-420-g005){#path5384-fig-0005}

Importantly, high levels of β‐catenin were detected in both mUM patients, which is related to tumour‐induced immune exclusion mechanisms [57](#path5384-bib-0057){ref-type="ref"}, [58](#path5384-bib-0058){ref-type="ref"}, [59](#path5384-bib-0059){ref-type="ref"}, suggesting an accessory mechanism by which tumours modulate infiltration and proliferation of lymphocytes in the metastatic site.

Among the immune phenotyping markers, we observed discrete, but positive, levels of CD163; high levels of CD68, HLA‐DR, and CD11c, and all macrophage and dendritic cell markers; and intermediate levels of the immune checkpoint PD‐L1 (Figure [5](#path5384-fig-0005){ref-type="fig"}B). The neutrophil marker CD66b was not detected in the selected ROIs, suggesting that neutrophils are not involved at least in the crosstalk between macrophages and T cells in these particular BAP1^−^ mUM cases. Lymphoid markers CD8A and CD4 were also found to be highly expressed. CD56 levels are relatively low compared with negative controls, suggesting absence of NK cells in the selected regions. However, T regulatory cells seem to be absent as intracellular levels of Foxp3 were not detected among these patients using this technique.

In addition, low positive levels of granzyme B were detected, together with high expression of B7‐H3, a checkpoint regulator of lymphocyte functions [60](#path5384-bib-0060){ref-type="ref"}. We also observed the expression of IDO‐1, TIGIT, and VISTA (Figure [5](#path5384-fig-0005){ref-type="fig"}B). IDO‐1 is known to induce adaptive resistance to anti‐PD1 and anti‐CTLA4 immunotherapies [61](#path5384-bib-0061){ref-type="ref"}, [62](#path5384-bib-0062){ref-type="ref"}. In addition, IDO and TIGIT were recently described to be expressed in pUM‐M3 with corresponding mUM tissues [63](#path5384-bib-0063){ref-type="ref"}.

Considered altogether, these findings suggest alternative mechanisms of T‐cell exhaustion other than PD‐1 and CTLA‐4 engagement, as well as the involvement of mechanisms for immune exclusion that may undertake an important role to support tumour immune evasion and, consequently, immunotherapy failure.

Discussion {#path5384-sec-0018}
==========

In this multi‐parametric immunophenotyping work in UM, we profiled the immune response of the 80 patients of the TCGA‐UM study, highlighting the involvement of *BAP1* loss in the coordination of gene expression of several immune markers. Selected biomarkers were further investigated in a smaller number of primary and metastatic BAP1^−^ UMs, at both transcriptome and protein levels, using cutting‐edge techniques. Recently, our group observed that different patterns of nuclear BAP1 expression in pUM provide insights into the prognostic significance of this tumour [64](#path5384-bib-0064){ref-type="ref"}. Among UMs with an M3 status, the cumulative survival of patients with UM expressing nuclear BAP1 is significantly greater than that of UM patients whose tumours are M3 with nuclear BAP1 loss. These findings and previous reports associating *BAP1* loss with a wide spectrum of cancers [65](#path5384-bib-0065){ref-type="ref"} underpin the molecular mechanisms behind the adverse prognostic effects of M3, supporting the importance of analysing immune gene expression from the aspect of *BAP1*loss in UM.

The genetic diversity of UM was recently described, including copy number variations (CNVs), somatic mutations, and *BAP1* alterations [63](#path5384-bib-0063){ref-type="ref"}. However, the diversity of immune gene expression is described by the tumour stroma (i.e. the features of the reactive cells in the tumour microenvironment), which shapes accordantly with the tumour phenotype (e.g. *BAP1* loss). As a consequence of *BAP1* loss in UM, tumour cells could therefore unleash metabolic mechanisms to secrete different factors that would induce the regulatory phenotype of T cells and macrophages in the tumour microenvironment (TME) to a more tolerogenic profile. The positive expression of MIF observed at the transcriptomic level in mUM is in accordance with previous reports showing that UM cells can secrete MIF as a mechanism of immune escape [66](#path5384-bib-0066){ref-type="ref"}. The main receptor of MIF in different immune cells is CD74 [36](#path5384-bib-0036){ref-type="ref"}, [67](#path5384-bib-0067){ref-type="ref"}. In addition, MIF was recently reported to induce M2 polarisation of TAMs, leading to immune suppression on several solid cancers [34](#path5384-bib-0034){ref-type="ref"}, [36](#path5384-bib-0036){ref-type="ref"}, [66](#path5384-bib-0066){ref-type="ref"}, [68](#path5384-bib-0068){ref-type="ref"}, [69](#path5384-bib-0069){ref-type="ref"}, [70](#path5384-bib-0070){ref-type="ref"}, [71](#path5384-bib-0071){ref-type="ref"}, [72](#path5384-bib-0072){ref-type="ref"}, and to downregulate the CTL responses [34](#path5384-bib-0034){ref-type="ref"}, which may occur via its interaction with the CD74 receptor expressed on CD8^+^ T cells in UM, as observed for cluster C. Since CD74 expression was not observed in the CD8^+^ T‐cell clusters of one BAP1^+^ pUM, we hypothesise that tumours with reduced expression of MIF or its receptor CD74 may contribute to increase the frequency of more effective CD8^+^ T cells in the TME of UM.

Therefore, modulation of T lymphocytes and macrophages toward an immunosuppressive phenotype could be explained by the expression of CD74 on these cells, which can be affected by suppressive factors derived from tumour cells, including MIF. CD74, which was highly expressed at the transcriptomic level in pUM, was also found at the protein level across the regulatory CD8^+^ T‐cell cluster and CD163^+^ M2‐like macrophage cluster. CD74 is a chaperone involved in the trafficking of HLA‐DR molecules to the surface of immune cells, and while it remains expressed on the surface of the cells, it may bind to MIF secreted by tumour cells in the TME [46](#path5384-bib-0046){ref-type="ref"}, [67](#path5384-bib-0067){ref-type="ref"}, [73](#path5384-bib-0073){ref-type="ref"}.

The pharmacological blockade of the MIF/CD74 interaction restores the TME immunogenic profile, as well as an effective anti‐tumour immune response against metastatic melanoma and gliomas [36](#path5384-bib-0036){ref-type="ref"}, [46](#path5384-bib-0046){ref-type="ref"}. The CD74 monoclonal blocking antibody milatuzumab is currently approved by the Food and Drug Administration (FDA) in the United States for the treatment of multiple myeloma, non‐Hodgkin lymphomas, and other CD74^+^ cancers [74](#path5384-bib-0074){ref-type="ref"}, [75](#path5384-bib-0075){ref-type="ref"}.

Changes in *BAP1* expression have also been associated with immune transformation in mesothelioma, and became a predictive tool for immunotherapy of peritoneal mesothelioma [76](#path5384-bib-0076){ref-type="ref"}, [77](#path5384-bib-0077){ref-type="ref"}. The impaired ability of thymic development and the proliferative responses of T lymphocytes in the context of *BAP1* inhibition are strong evidence that loss of *BAP1* function is associated with immune suppression and systemic myeloid transformation [16](#path5384-bib-0016){ref-type="ref"}, [78](#path5384-bib-0078){ref-type="ref"}.

In this study, we also observed that increased transcriptome levels of CD38, HLA‐DRA, IDO1, and LAG‐3 are significantly correlated with *BAP1* loss. These immune biomarkers are of extreme importance because they have been associated with different immune‐suppressive pathways, which suggests mechanistic insights for immune suppression and immunotherapy resistance using ICIs [30](#path5384-bib-0030){ref-type="ref"}, [36](#path5384-bib-0036){ref-type="ref"}, [37](#path5384-bib-0037){ref-type="ref"}, [38](#path5384-bib-0038){ref-type="ref"}, [41](#path5384-bib-0041){ref-type="ref"}. In the protein single‐cell level, we show the functional state of UM infiltrating CD8^+^ T cells, which co‐express high levels of CD38, HLA‐DR, and CD28. The co‐expression of HLA‐DR/CD28 in CD8^+^ T cells suggests that these lymphocytes are distinct from cytolytic effector T cells [30](#path5384-bib-0030){ref-type="ref"}, and can be classified as regulatory CD8^+^ T cells, with similar functions to classical CD4^+^Foxp3^+^ cells [28](#path5384-bib-0028){ref-type="ref"}. In addition, higher levels of CD38 demarcates regulatory and memory status to CD8^+^ T cells in the context of IFN‐γ‐mediated immunosuppression, and was recently addressed to drive mechanisms of tumour‐mediated immune escape to immunotherapies using PD1/PD‐L1 blockade [37](#path5384-bib-0037){ref-type="ref"}, [38](#path5384-bib-0038){ref-type="ref"}. Indeed, IFN‐γ is upregulated in the context of *BAP1* loss and is widely associated with several immune‐suppressive network categories, which is in accordance with recent reports showing the immune‐suppressive roles of IFN‐γ [79](#path5384-bib-0079){ref-type="ref"}.Therefore, targeting CD38 in UM may be considered a suitable strategy to improve the efficacy of immunotherapy using ICI in metastatic UM. A recent study showed that targeting CD38 using isatuximab can preferentially block immunosuppressive T‐regulatory lymphocytes and therefore restore immune effector function against multiple myeloma [53](#path5384-bib-0053){ref-type="ref"}.

The low expression of ICRs LAG‐3 and CTLA‐4 among the majority of T‐cell clusters suggests that these lymphocytes may not be exhausted but exist in a lower activation state in pUM [80](#path5384-bib-0080){ref-type="ref"}, [81](#path5384-bib-0081){ref-type="ref"}, [82](#path5384-bib-0082){ref-type="ref"}, [83](#path5384-bib-0083){ref-type="ref"}. Increased transcriptome levels of LAG‐3 in the TCGA‐UM study could be linked with LAG‐3 expression among CD25^+^ B‐cell clusters as evidenced by mass cytometry, suggesting a memory and natural regulatory phenotype for these cells [84](#path5384-bib-0084){ref-type="ref"}, [85](#path5384-bib-0085){ref-type="ref"}. Moreover, higher expression of IDO1 in both pUM and mUM suggests this molecule as an important adjuvant target for immunotherapy using ICIs, since IDO1 blockade has been shown to synergise the therapeutic effector of both CTLA‐4 and PD1/PD‐L1 inhibitors [61](#path5384-bib-0061){ref-type="ref"}.

Our findings in this report also provide evidence that *BAP1* ^−^ pUM could shape an immune response similar to that in mUM tissues, since *BAP1*‐loss‐correlated immune genes are similarly expressed in mUM, as observed using the NanoString approach. Furthermore, the DSP approach revealed that additional ICI‐resistant mechanisms not necessarily related to *BAP1* changes may also be important in mUM‐induced exclusion of immune cells, such as the Wnt/β‐catenin axis [58](#path5384-bib-0058){ref-type="ref"}, [59](#path5384-bib-0059){ref-type="ref"}. A recent study showed that hepatocellular carcinoma patients displaying an altered Wnt/β‐catenin pathway were refractory to immune‐checkpoint blockade [86](#path5384-bib-0086){ref-type="ref"}, which is aligned with evidence that melanoma‐intrinsic β‐catenin signalling prevents anti‐tumour immunity [87](#path5384-bib-0087){ref-type="ref"}.

It is important to highlight that a weakness of this study is the low number of analysed *BAP1* ^−^ UM samples for CyTOF studies. The reason behind that is the scarcity of the type of fresh tumour sample, not only because this type of tumour is very rare but also because the tissues must be sufficiently large to provide significant amounts of immune infiltrated cells for further downstream analysis, and thus reducing the sample size of this study. Despite this, we could not only reproduce and confirm previous data published regarding the higher frequency of infiltrated CD8^+^ T cells over CD4^+^ T cells at the transcriptomic and protein levels [4](#path5384-bib-0004){ref-type="ref"}, [15](#path5384-bib-0015){ref-type="ref"}, but also detect the expression of specific immune markers initially detected in the transcriptome analysis of the larger TCGA‐UM cohort (*n* = 80), and also observed in mUM tissues, expanding the impact of our pUM mass cytometry findings.

The present work shows an improved overview of the immune profile of pUM and mUM at both transcriptome and protein levels and suggests that immune modulation in UM may be driven by loss of *BAP1* expression. Immunosuppressive networks found in *BAP1* ^−^ tumours may not only influence the quality and quantity of local anti‐tumour immune responses but also affect immunotherapy outcomes using ICIs, leading to regulation or exclusion of T effector lymphocytes, as well as alternative polarisation of macrophages toward a tolerogenic phenotype in the TME. The relative importance of these findings will require further functional validation, and this study provides the solid ground to initiate these studies. Detected key immune biomarkers, such as CD38 and CD74, could be immediately investigated for functional validation in the adjuvant settings of ICI immunotherapies, since there are currently available FDA‐approved inhibitors against these targets [53](#path5384-bib-0053){ref-type="ref"}, [74](#path5384-bib-0074){ref-type="ref"}. Altogether, this work provides the most critical immune markers and pathways to consolidate the type of immune responses in the context of *BAP1* loss in UM. This may help us to understand why this type of cancer is one of the most refractory to current immunotherapies using ICIs at present.
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